

INVITROGEN CORP  
Form 8-K  
May 30, 2003

**Table of Contents**

---

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**  
Date of Report (Date of Earliest Event Reported): May 30, 2003

**INVITROGEN CORPORATION**

---

(Exact name of registrant as specified in its charter)

**Delaware**

**0-25317**

**33-0373077**

(State or other jurisdiction of incorporation)

(Commission File No.)

(IRS Employer Identification No.)

**1600 Faraday Avenue, Carlsbad, CA**

**92008**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: **(760) 603-7200**

Not Applicable

(Former name or former address, if changed since last report)

---

---

---

**TABLE OF CONTENTS**

Item 5. OTHER EVENTS.

Item 7. FINANCIAL STATEMENTS AND EXHIBITS.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. OTHER EVENTS.**

On May 30, 2003, Invitrogen Corporation ( Invitrogen ) announced the appointment of Gregory T. Lucier as its President and Chief Executive Officer. Mr. Lucier also has been appointed to Invitrogen s Board of Directors. Mr. Lucier has succeeded James R. Glynn as President and Chief Executive Officer, and Mr. Glynn has resigned as Chief Executive Officer, President and Chief Operating Officer concurrent with the appointment of Mr. Lucier. Mr. Glynn will serve as Chief Executive Officer Emeritus until June 30, 2003, and will remain on Invitrogen s Board of Directors.

A copy of the press release announcing appointment of Mr. Lucier as President and Chief Executive Officer is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 7. FINANCIAL STATEMENTS AND EXHIBITS.**

(c) Exhibits

<b>Exhibit</b>	<b>Description</b>
99.1	Press Release, dated May 30, 2003, announcing appointment of Mr. Lucier as President and Chief Executive Officer.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Invitrogen Corporation**

Date: May 30, 2003

By:           /s/ John A. Cottingham          

John A. Cottingham  
Vice President, General Counsel and Secretary

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description</b>
99.1	Press Release, dated May 30, 2003, announcing appointment of Mr. Lucier as President and Chief Executive Officer.